Voyager Therapeutics, Inc.
NASDAQ:VYGR
7.1 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Voyager Therapeutics, Inc. |
Symbool | VYGR |
Munteenheid | USD |
Prijs | 7.1 |
Beurswaarde | 387,186,430 |
Dividendpercentage | 0% |
52-weken bereik | 5.71 - 11.72 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alfred W. Sandrock Jr., M.D., Ph.D. |
Website | https://www.voyagertherapeutics.com |
An error occurred while fetching data.
Over Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)